Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Research & Development (2021 - 2025)

SAB Biotherapeutics' Research & Development history spans 5 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 40.21% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $34.4 million, up 12.81%, while the annual FY2025 figure was $34.4 million, 13.56% up from the prior year.
  • Research & Development reached $10.7 million in Q4 2025 per SABSW's latest filing, up from $9.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $18.7 million in Q2 2021 to a low of $3.7 million in Q2 2023.
  • Average Research & Development over 5 years is $8.7 million, with a median of $7.7 million recorded in 2024.
  • Peak YoY movement for Research & Development: plummeted 65.96% in 2023, then surged 94.81% in 2024.
  • A 5-year view of Research & Development shows it stood at $10.6 million in 2021, then tumbled by 32.96% to $7.1 million in 2022, then tumbled by 39.8% to $4.3 million in 2023, then soared by 78.05% to $7.7 million in 2024, then skyrocketed by 40.21% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Research & Development are $10.7 million (Q4 2025), $9.0 million (Q3 2025), and $7.0 million (Q2 2025).